CIK 0001755237 · Non-accelerated filer<br>Smaller reporting company
Korsana Biosciences, Inc.
Sign in to watch- Ticker
- KRSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- MA
- Entity type
- operating
- EIN
- 831895370
- Phone
- (781) 516-2325
- Business address
- 203 CRESCENT STREET, BLDGS. #3/3A/4, SUITE 503, WALTHAM, MA, 02453
- Former names
- Cyclerion Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-11-30 | Hecht Peter M Director | Grant or award | +20,000 | 347,385 | ||
| 2023-11-30 | DESOUZA ERROL B Director | Grant or award | +20,000 | 50,000 | ||
| 2023-11-30 | DESOUZA ERROL B Director | Grant or award | +30,000 | 30,000 | ||
| 2023-11-30 | Hyman Steven Director | Grant or award | +20,000 | 20,000 | ||
| 2023-08-09 | MCGUIRE TERRANCE Director | Sale | −8 | $3.40 | $27 | 0 |
| 2023-05-19 | Hecht Peter M Chief Executive Officer | Grant or award | +225,000 | $8.68 | $2.0M | 327,385 |
| 2023-05-19 | Hecht Peter M Chief Executive Officer | Grant or award · Series A Convertible Preferred Stock | +351,037 | $8.68 | $3.0M | 351,037 |
| 2022-07-25 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +57,753 | 57,753 | ||
| 2022-07-25 | Hyman Steven Director | Grant or award · Stock Option (Right to Buy) | +57,753 | 57,753 | ||
| 2022-06-14 | MCGUIRE TERRANCE Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | Mendelsohn Michael Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | Fanucci Marsha Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | Lovell Stephanie Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | CONRADES GEORGE H Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | Isacson Ole Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-06-14 | DESOUZA ERROL B Director | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2022-01-20 | Busch Andreas Chief Scientific Officer | Grant or award · Employee Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2022-01-20 | Gjino Anjeza Chief Financial Officer | Grant or award · Employee Stock Option (Right to Buy) | +135,000 | 135,000 | ||
| 2022-01-20 | Hecht Peter M Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +430,000 | 430,000 | ||
| 2022-01-20 | Gault Cheryl Chief Operating Officer | Grant or award · Employee Stock Option (Right to Buy) | +135,000 | 135,000 |
Page 2 of 9 · 167 trades